The significant clinical success in the GLOW2 study and the accelerated BLA timeline are major value drivers that overshadow the modest EPS miss. The strengthened cash position supports the company's ambitious development plans. Traders should focus on upcoming catalysts: topline data from the DAYBREAK study (wet AMD) expected in Q3 2026 and from the PEAK study (MESI) in Q4 2026.
Price Chart
Executive Summary
Kodiak Sciences reported Q4 2025 net loss of $56.7M ($1.04/share), missing consensus by $0.03, driven by increased R&D spend. The filing was dominated by positive clinical news: strong Phase 3 GLOW2 topline results for Zenkuda (tarcocimab) in diabetic retinopathy, showing 62.5% of patients achieved ≥2-step improvement in DRSS vs. 3.3% for sham (p<0.0001), with an 85% risk reduction in sight-threatening complications. The company announced an accelerated path toward a multi-indication BLA submission and ended the year with $209.9M in cash after a $173M equity raise.
Key Financial Metrics
Key Facts
- Positive Phase 3 GLOW2 topline results for Zenkuda in diabetic retinopathy: 62.5% of patients achieved ≥2-step improvement in DRSS vs. 3.3% for sham (p<0.0001).
- 85% risk reduction in sight-threatening complications with Zenkuda vs. sham (2.4% vs. 15.8%, p=0.0001).
- Company announced an accelerated timeline for a multi-indication Biologics License Application (BLA) submission for Zenkuda.
- Completed a $173M follow-on equity offering in December 2025, ending the year with $209.9M in cash, up from $72.0M in Q3.
- Q4 2025 net loss was $56.7M ($1.04/share), missing consensus of $-1.01/share, due to higher R&D expenses of $45.5M (up from $31.8M YoY).
Financial Impact
Net loss of $56.7M ($1.04/share) for Q4 2025, missing consensus by $0.03. R&D expenses increased 43% YoY to $45.5M. Cash position improved to $209.9M after a $173M equity raise.
Risk Factors
- The stock has a high short interest, and future dilution is possible as the company will likely need to raise more capital to fund late-stage trials and a potential commercial launch.
- The upcoming DAYBREAK study in wet AMD is a critical hurdle; failure to meet its primary endpoint could significantly impact the stock despite the GLOW2 success.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-134854 |
| Document: kod-20260331.htm | 0001193125-26-134854 |
| Document: 0001193125-26-134854-index-headers.html | 0001193125-26-134854 |
| Document: 0001193125-26-134854-index.html | 0001193125-26-134854 |
| Document: 0001193125-26-134854.txt | 0001193125-26-134854 |
| 8-K Data (Synthetic) | 0001193125-26-134854 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 13, 2026 7w ago | 8-K | $41.35 $33.14 | ▼ −19.85% | ▼ −17.86% | $94.45 (+128.42%) |
Aug 13, 2026 7w ago | Press Release | $41.35 $33.14 | ▼ −19.85% | ▼ −17.86% | $94.45 (+128.42%) |
Jun 11, 2026 16w ago | Institutional Cluster | $33.97 $40.08 | ▲ +17.99% | ▲ +16.10% | $94.45 (+178.04%) |
May 7, 2026 21w ago | 8-K | $41.01 $31.05 | ▼ −24.29% | ▼ −24.31% | $94.45 (+130.31%) |
Mar 31, 2026 26w ago | 8-K | $42.81 $43.67 | ▲ +2.01% | ▼ −7.71% | $94.45 (+120.63%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access